| human breast cancer (BT474) and human prostate
cancer (22Rv1) |
iRGD–ABX (conjugated) |
albumin and doxorubicin liposomes |
130/120 nm |
conjugated
or coadministration |
(194) |
| |
iRGD+ABX (combination) |
|
|
|
|
| |
DOX liposomes+iRGD (combination) |
|
|
|
|
| |
| pancreatic ductal adenocarcinoma (PDAC) |
irinotecan-loaded silicasome |
silicasome |
130 nm |
coadministration |
(201) |
| |
| murine breast cancer (4T1) |
IDDHN,
hyaluronic acid (HN) shell |
dendrimer |
35–150 nm |
coadministration |
(198) |
| |
+dendri-graft-l-lysine conjugated with doxorubicin and
indocyanine (IDD) |
|
|
|
|
| |
| murine breast cancer (4T1) |
iRGD/AuNPs-A&C |
gold |
|
coadministration |
(413) |
| |
| murine breast cancer (4T1) |
iNP/IT |
lipid-polymer hybrid |
112 nm |
conjugated |
(199) |
| |
(iRGD-conjugated
NP |
|
|
|
|
| |
loaded with ICG and TPZ) |
|
|
|
|
| |
| human liver cancer (HepG2) |
DOX+SOR/iRGD NPs |
lipid-polymer hybrid |
126 nm |
conjugated |
(202) |
| |
| murine colon cancer (colon-26) |
iRGD-PEG-NPs |
polymeric |
280 nm |
conjugated |
(203) |
| |
(CPT-loaded) |
|
|
|
|
| |
| human colon cancer (lovo-6-luc-1) /human gastric cancer (MKN45)/ |
iRGD/DOX |
liposomes |
not reported |
coadministration |
(204) |
| human ovarian cancer (IGROV-1) |
|
|
|
|
|
| |
| human ovarian cancer (OVCAR-8) /human schwannoma (HEI-193) |
iRGD-transportan-siRNA |
peptides/siRNA |
80 nm |
conjugated |
(205) |
| |
| human breast cancer (MCF10CA1a) /pancreatic ductal
adenocarcinoma
(KRAS-Ink) /human prostate cancer (PC-3) |
ZHA-QDs |
quantum |
12 nm |
coadministration |
(207) |
| |
|
|
|
|
|
| |
|
dots |
|
|
|
| |
| human prostate cancer (PC3-MM2) |
Psi-NPs |
silicon |
202 nm |
conjugated |
(209) |
| |
| murine breast cancer (4T1) |
iRGD-NDs iRGD-NPs |
carbon |
ND = 10 nm |
conjugated |
(200) |
| |
|
|
NP = 70 nm |
|
|
| |
| pregnancy complications |
FAM-iRGD |
iron oxide |
180 nm |
conjugated |
(206) |
| |
|
nanoworms |
|
|
|
| |
| pregnancy complications |
liposome-iRGD |
liposomes |
146 nm |
conjugated |
(206) |
